Results 61 to 70 of about 15,810 (189)
Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez +4 more
wiley +1 more source
Italian nationwide survey on pseudomonas aeruginosa from invasive infections: Activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers [PDF]
Objectives: Pseudomonas aeruginosa is a major cause of severe healthcare-associated infections and often shows MDR phenotypes. Ceftolozane/tazobactam is a new cephalosporin/b-lactamase inhibitor combination with potent activity against P.
Dusi P. A. +29 more
core +3 more sources
ABSTRACT Early prenatal screening at 26 + 6 weeks detected Citrobacter koseri vaginal colonization in an asymptomatic high‐risk gravida. Culture‐guided IV ceftazidime (susceptible per CLSI testing) eradicated the pathogen without maternal/fetal compromise.
Mario Assenza +2 more
wiley +1 more source
Ceftolozane/tazobactam – the "new player" in a battle against multiresistant pathogens [PDF]
Ceftolozane/tazobactam is a new combined antibacterial agent for the treatment of infections caused by gram-negative microorganisms, P. aeruginosa in particular, including strains resistant to other clinically available antimicrobials.
Golub A.V., Kozlov R.S.
doaj +1 more source
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov +7 more
wiley +1 more source
We investigated the in vitro activity of various antimicrobial combinations against carbapenem-resistant Acinetobacter baumannii (CRAB) isolates. The in vitro activity of six two-drug combinations against CRAB isolates collected from the blood samples of
Yong Guk Ju +5 more
doaj +1 more source
ABSTRACT Fluoroquinolones (FQs) are among the most frequently prescribed antibiotic classes worldwide. Despite their therapeutic versatility in treating bacterial infections, regulatory authorities recognized risks of persistent and potentially irreversible adverse effects, particularly peripheral neuropathy (PN).
Nimra Shamim +5 more
wiley +1 more source
This scoping review with textual analysis maps antimicrobial resistance in Salmonella across aquaculture, seafood, and related aquatic environments. Across 93 studies, recurrent MDR patterns suggest sentinel serotypes (S. Typhimurium, S. Newport) and a minimal antimicrobial susceptibility testing (AST) panel to guide matrix‐stratified One Health ...
Cristiane Coimbra de Paula +8 more
wiley +1 more source
Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
Objectives: To assess the probability of reaching adequate pharmacokinetic/pharmacodynamics values for ceftolozane/tazobactam at different doses and degrees of renal functions in patients with Pseudomonas aeruginosa bacteremia.
Jesus Ruiz +6 more
doaj +1 more source
Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation [PDF]
Ceftolozane-tazobactam has potent activity against Pseudomonas aeruginosa , a pathogen associated with cystic fibrosis (CF) acute pulmonary exacerbations (APE).
Muhlebach, Marianne +5 more
core +1 more source

